Navigation Links
Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
Date:10/2/2007

- Company to Present Four Posters at Medical Conference in San Diego,

October 4

- 7, 2007 -

CHICAGO, Oct. 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, will present four posters at the Infectious Diseases Society of America (IDSA) 45th Annual Meeting in San Diego, October 4-7. IDSA Annual Meetings typically feature cutting-edge, breakthrough science and provocative presentations on infectious diseases discoveries, treatments and cures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

This year, Advanced Life Sciences' poster presentations will report data regarding the clinical safety and efficacy of cethromycin in selected human clinical trials including drug-drug interaction studies, oral suspension formulation studies and in pharyngitis/tonsillitis therapeutic studies in patients 12 years of age or older.

IDSA is an organization of physicians, scientists and other health care professionals who specialize in infectious diseases. Its purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health and prevention relating to infectious diseases. The Society was founded in 1963 and has approximately 8,000 members.

Presentation Schedule

Friday, October 5, 2006 - 12:30-2:00 pm PT - Halls G-H

Session 051 "Antimicrobial Agents"

-- Poster 442--A Phase 3 Comparative Study of the Safety & Efficacy of

Cethromycin 150 mg QD and Penicillin V 500 mg TID for the Treatment of

Streptococcal Pharyngitis/Tonsillitis

-- Poster 443--Assessment of the Pharmacokinetic Interaction between

Cethromycin and Rifampin

-- Poster 444--Assessment of the Pharmacokinetic Interaction between

Cethromycin and Ketoconazole

-- Poster 450--Single-Dose Bioavailability of Cethromycin Granules for

Suspension Formulation in Healthy Adult Subjects

About Cethromycin

Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.

The Company conducted two, pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. In June of 2007, Advanced Life Sciences released positive results from the first of these two trials, Trial CL-06, which showed that cethromycin met primary and secondary clinical endpoints. The Company expects data from the second trial, CL-05 to be reported in the Fall. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
2. Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option
3. 384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler
4. WARF expands license agreement with Advanced Cell Technology
5. Rockwells $1M gift to UWM will support advanced automation research
6. Advanced CIO: Technology execs must trumpet their success
7. FDA approves advanced digital mammography system
8. Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield
9. Wisconsins insurance companies use advanced IT to speed relief
10. $60 Million Available in Advanced Tech Competition
11. Advanced Life Sciences to Hit the Road For $30 Million in Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... CHICAGO , December 5, 2016 ... report, "Cell Expansion Market, by Products (Consumable, Instruments, ... Applications (Regenerative Medicine and Stem Cell Research, Cancer, ... Research Institutes, Cell Banks) - Global Revenue, Trends, ... by Scalar Market Research, the global cell expansion ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):